



16 DEC 2019

FDA ADVISORY  
No. 2019-518

**TO: THE GENERAL PUBLIC**

**SUBJECT: Public Health Warning on the Presence of Tadalafil in BRAVO Maca + Jatropha + Corynaea Crassa Food Supplement for Men**

The public is hereby informed that the Food and Drug Administration (FDA) has conducted sampling of specific batches of **BRAVO Maca + Jatropha + Corynaea Crassa Food Supplement for Men** as part of the strengthened post-marketing surveillance of this Office.



The analyses of the FDA Laboratory showed that the aforementioned product under the specific lot number **ABV38F26T** and expiry date **26 February 2021** have tested positive for **Tadalafil**. **Tadalafil** is a prescription drug used to treat male sexual function problems such as impotence or erectile dysfunction (ED).

**Tadalafil** is prohibited in food/dietary supplements, since it poses potential health risks to the unwary consuming public especially those who have had a stroke, severe vision loss, persons experiencing stomach ulcers, heart problems, kidney problems, liver problems, bleeding problem, blood cell problems, and low or high blood pressure. Possible side effects which can occur are as follows:

- indigestion
- muscle aches
- flushing
- back pain
- stuffy or runny nose
- headaches



The presence of drug ingredient **Tadalafil** deems the food/dietary supplement as **ADULTERATED**, which is in violation of R.A. 9711 (FDA Act of 2009) and R.A. 10611, otherwise known as the Food Safety Act of 2013.

Consumers are advised to:

1. Stop taking BRAVO Maca + Jatropha + Corynaea Crassa Food Supplement for Men with lot number **ABV38F26T**.
2. Consult a healthcare professional in case you experience any of the side effects upon consumption of the product.
3. Exercise caution when purchasing food supplements for men that can be potentially adulterated with drug ingredients which can seriously harm the consumers.

Further, the public who purchased BRAVO Maca + Jatropha + Corynaea Crassa Food Supplement for Men is advised to immediately coordinate with FDA at telephone number 857-1900 local 8105 or email us at [cfr@fda.gov.ph](mailto:cfr@fda.gov.ph). To report continuous sale or distribution of unregistered health products, kindly email us at [report@fda.gov.ph](mailto:report@fda.gov.ph).

  
**ROLANDO ENRIQUE D. DOMINGO, MD, DPBO**  
Officer-in-Charge, Director General



*DTN 20191209123647*